Multiple myeloma (MM) is the second-most common haematological malignancy, is characterised by expansion of malignant plasma cells and remains incurable. Haematopoietic stem cell transplantation (HSCT) is the only potentially curative treatment for MM patients. The efficacy of HSCT is largely derived from the graft-versus-myeloma (GVM) effect: an eradiation of myeloma cells by the donor immune cells. In the early post-HSCT period, the reconstitution of immunocompetent donor T cells not previously tolerized to the recipient’s myeloma is crucial component for generating an effective GVM response. Our evidence from autologous (auto)-HSCT suggests that myeloma during lymphopenic state of post-HSCT induces changes in CD4+T cell gene expression profile, with potential impact on survival, activation, migration and effector function of CD4+T cells. This project will test hypothesis that early post-HSCT period could ‘reset’ myeloma-CD4+T cell relations and mark an ideal settings for GVM responses.
- Haematological malignancy, Multiple Myeloma
- Some components of this project are suitable for Honours students, flexible for clinical students and entire project is suitable for PhD students.